222 related articles for article (PubMed ID: 23802997)
1. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
[TBL] [Abstract][Full Text] [Related]
2. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
Juurlink DN; Gomes T; Shah BR; Mamdani MM
Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
[TBL] [Abstract][Full Text] [Related]
3. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
Abdelmoneim AS; Eurich DT; Senthilselvan A; Qiu W; Simpson SH
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
[TBL] [Abstract][Full Text] [Related]
4. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
[TBL] [Abstract][Full Text] [Related]
5. The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.
Clemens KK; McArthur E; Dixon SN; Fleet JL; Hramiak I; Garg AX
Can J Diabetes; 2015 Aug; 39(4):308-16. PubMed ID: 25840942
[TBL] [Abstract][Full Text] [Related]
6. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Khalangot M; Tronko M; Kravchenko V; Kovtun V
Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
[TBL] [Abstract][Full Text] [Related]
8. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemia in hospitalized patients treated with sulfonylureas.
Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC
Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
[TBL] [Abstract][Full Text] [Related]
10. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
[TBL] [Abstract][Full Text] [Related]
11. Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?
Nagendran J; Oudit GY; Bakal JA; Light PE; Dyck JR; McAlister FA
Diabetes Obes Metab; 2013 Nov; 15(11):1022-8. PubMed ID: 23668425
[TBL] [Abstract][Full Text] [Related]
12. Sulphonylureas and cancer: a case-control study.
Monami M; Lamanna C; Balzi D; Marchionni N; Mannucci E
Acta Diabetol; 2009 Dec; 46(4):279-84. PubMed ID: 19082520
[TBL] [Abstract][Full Text] [Related]
13. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Monami M; Balzi D; Lamanna C; Barchielli A; Masotti G; Buiatti E; Marchionni N; Mannucci E
Diabetes Metab Res Rev; 2007 Sep; 23(6):479-84. PubMed ID: 17385195
[TBL] [Abstract][Full Text] [Related]
14. Is gliclazide a sulfonylurea with difference? A review in 2016.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
[TBL] [Abstract][Full Text] [Related]
15. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
Sadikot SM; Mogensen CE
Diabetes Res Clin Pract; 2008 Dec; 82(3):391-5. PubMed ID: 18945509
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
[TBL] [Abstract][Full Text] [Related]
17. Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study.
Weir MA; Gomes T; Mamdani M; Juurlink DN; Hackam DG; Mahon JL; Jain AK; Garg AX
Nephrol Dial Transplant; 2011 Jun; 26(6):1888-94. PubMed ID: 20974644
[TBL] [Abstract][Full Text] [Related]
18. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
Lee YH; Lee CJ; Lee HS; Choe EY; Lee BW; Ahn CW; Cha BS; Lee HC; Balkau B; Kang ES
Diabetes Metab; 2015 Jun; 41(3):208-15. PubMed ID: 25687901
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
[TBL] [Abstract][Full Text] [Related]
20. Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients.
Khalangot M; Kovtun V
Curr Diabetes Rev; 2014; 10(5):336-42. PubMed ID: 25336066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
